applsci-logo

Journal Browser

Journal Browser

Drug Development for Cancer, Diabetes and Obesity

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (10 December 2021) | Viewed by 4181

Special Issue Editor


E-Mail Website
Guest Editor
Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro s/n, Col. Narciso Mendoza, Reynosa 88710, Tamaulipas, Mexico
Interests: medicinal chemistry; synthetic organic chemistry; immunology of infectious diseases; medicinal and pharmaceutical chemistry; antibodies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Currently, cancer, diabetes, and obesity are a group of diseases considered as pandemics, although their classification and cause are different. These diseases have a different impact on public health in each country. Although these diseases can be prevented and controlled, they are currently causing high morbidity and mortality rates. Despite its importance, current pharmacological treatment has unreliable efficacy and is producing numerous undesirable secondary effects. Therefore, there is an urgent need to develop new therapeutic options that are safer and more effective.

In the last two decades, new strategies in drug discovery have been implemented to combat cancer, diabetes, and obesity. Despite these facts and the impressive advances in understanding the biology of these diseases, only a limited number of compounds are currently in clinical trials. Therefore, there is an urgent need to develop new therapeutic options that will help to increase effectiveness, decrease cost, and facilitate availability.

This Research Topic seeks manuscripts dealing with novel approaches in the discovery and development of drugs for cancer, diabetes, and obesity. By considering both original research and review articles that could have an ever-increasing impact on the drug discovery pipeline, new trends could be discovered that would impact the field in the near future. Areas to be covered in this Research Topic may include but are not limited to the following:

  • Bioactive compounds;
  • Computer-aided drug design;
  • Synthesis and biological activity of small molecules;
  • Drug targets;
  • Drug repositioning.

Prof. Dr. Gildardo Rivera Sanchez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • diabetes
  • obesity
  • drug design
  • drug repositioning
  • molecular docking
  • molecular dynamic
  • bioinformatics
  • synthesis
  • biomolecules
  • targets
  • in vitro assays
  • in vivo assays
  • small molecules
  • peptides
  • natural products
  • mechanism of action
  • preclinical assays
  • clinical assays

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3099 KiB  
Article
A Short S-Equol Exposure Has a Long-Term Inhibitory Effect on Adipogenesis in Mouse 3T3-L1 Cells
by Gilberto Mandujano-Lázaro, Carlos Galaviz-Hernández, César A. Reyes-López, Julio C. Almanza-Pérez, Abraham Giacoman-Martínez, César López-Camarillo, Fengyang Huang and Laurence A. Marchat
Appl. Sci. 2021, 11(20), 9657; https://doi.org/10.3390/app11209657 - 16 Oct 2021
Cited by 4 | Viewed by 3606
Abstract
In the search for new drugs against obesity, the chronic disease that threatens human health worldwide, several works have focused on the study of estrogen homologs because of the role of estrogen receptors (ERs) in adipocyte growth. The isoflavone equol, an ERβ agonist, [...] Read more.
In the search for new drugs against obesity, the chronic disease that threatens human health worldwide, several works have focused on the study of estrogen homologs because of the role of estrogen receptors (ERs) in adipocyte growth. The isoflavone equol, an ERβ agonist, has shown beneficial metabolic effects in in vivo and in vitro assays; however, additional studies are required to better characterize its potential for body weight control. Here, we showed that the treatment of 3T3-L1 cells with 10 μM of S-equol for the first three days of the adipocyte differentiation protocol was able to prevent cells becoming semi-rounded and having a lipid droplet formation until the seventh day of culture; moreover, lipid accumulation was reduced by about 50%. Congruently, S-equol induced a reduction in mRNA expression of the adipogenic markers C/EBPα and PPARγ, and adipokines secretion, mainly Adiponectin, Leptin, Resistin, and MCP-1, while the release of PAI-1 was augmented. Moreover, it also reduced the expression of ERα and attenuated the subexpression of ERβ associated with adipogenesis. Altogether, our data suggested that S-equol binding to ERβ affects the transcriptional program that regulates adipogenesis and alters adipocyte functions. Future efforts will focus on studying the impact of S-equol on ER signaling pathways. Full article
(This article belongs to the Special Issue Drug Development for Cancer, Diabetes and Obesity)
Show Figures

Figure 1

Back to TopTop